International Journal of Molecular Sciences (Dec 2022)

Nrf2 Pathway in Huntington’s Disease (HD): What Is Its Role?

  • Paolo Tucci,
  • Roberta Lattanzi,
  • Cinzia Severini,
  • Luciano Saso

DOI
https://doi.org/10.3390/ijms232315272
Journal volume & issue
Vol. 23, no. 23
p. 15272

Abstract

Read online

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease that occurs worldwide. Despite some progress in understanding the onset of HD, drugs that block or delay symptoms are still not available. In recent years, many treatments have been proposed; among them, nuclear transcriptional factor-2 (Nrf2) enhancer compounds have been proposed as potential therapeutic agents to treat HD. Nrf2 triggers an endogenous antioxidant pathway activated in different neurodegenerative disorders. Probably, the stimulation of Nrf2 during either the early phase or before HD symptoms’ onset, could slow or prevent striatum degeneration. In this review, we present the scientific literature supporting the role of Nrf2 in HD and the potential prophylactic and therapeutic role of this compound.

Keywords